COLL Stock Analysis: Buy, Sell, or Hold?
COLL - Collegium Pharmaceutical, Inc. Common Stock
$32.84
0.40 (1.22%)
▲
5d:
-5.47%
30d:
-21.2%
90d:
-34.12%
HOLD
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
COLL is down 7.1% this week, but smart money is accumulating calls. Top strike: $40 2026-06-18 with 16 OI. Call ratio: 100% View Scanner →
Strength: 8.6/10
Get Alerted When COLL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: COLL shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: COLL shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$29.63
Based on -4.2% avg growth
INTRINSIC VALUE TODAY
$18.40
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 5.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: COLL is currently trading at $32.84, which is considered oversold relative to its 30-day fair value range of $33.68 to $42.35. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.1) compared to its historical average (5.8). Remarkably, the market is currently pricing in an annual earnings decline of 4.4% over the next few years. This pessimistic expectation contrasts with the company's recent 31.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, COLL is in a downtrend. The price is currently testing key support at $32.73. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: COLL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $54.17 (+67.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, COLL is in a downtrend. The price is currently testing key support at $32.73. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: COLL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $54.17 (+67.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$33.68 -
$42.35
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
92.3%
Protect Your Profits
Holding COLL? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 67.0% below Wall St target ($54.17)
- CAUTION: Recommendation downgraded due to -5.5% 5-day decline
Fair Price Analysis
30-Day Fair Range
$33.68 -
$42.35
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$2.06
(6.3%)
Support & Resistance Levels
Support Level
$32.73
Resistance Level
$37.06
Current Trend
Downtrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.08
Wall Street Target
$54.17
(+67.0%)
Revenue Growth (YoY)
12.9%
Earnings Growth (YoY)
31.5%
Profit Margin
8.1%
Valuation Discount vs History
-4.4% cheaper
PE vs Historical
5.1 vs 5.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.4%
(market-implied from PE analysis)
1-Year Target
$31.01
(-4%)
2-Year Target
$29.65
(-9%)
3-Year Target
$28.34
(-13%)
3-Yr Target (if PE normalizes)
(PE: 5→6)
$32.37
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: -12.4%)
$104.32
(+222%)
Base:
(SPY PE: 5.1, Growth: -12.4%)
$23.65
(-27%)
Bear:
(PE: 4.3, Growth: -12.4%)
$20.10
(-38%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (20x PE), but valuation improves significantly next year (5x PE) as earnings recover.
Trailing PE: 20.49 | Current EPS (TTM): $1.73
Bull Case
$77.97
(+125%)
Analyst growth 100.0%, PE expands to 22.5
Base Case
$70.88
(+104%)
Market implied 100.0%, PE stable at 20.5
Bear Case
$24.10
(-31%)
Severe decline -20.0%, PE contracts to 17.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.1 to 5.8
Stabilization Target:
$37.05
(+14.2%)
PE Expansion Potential:
+14.2%
Share & Embed Analysis
Last updated: March 30, 2026 10:08 AM ET
Data refreshes hourly during market hours. Next update: 11:08 AM
Data refreshes hourly during market hours. Next update: 11:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is COLL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Scott Dreyer
SELL
49976 shares
2026-03-03
Scott Dreyer
SELL
17600 shares
2025-12-08
Rita J Balice-Gordon
SELL
3650 shares
2025-12-05
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 55 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 60 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 58 HOLD |
Advanced COLL Option Strategies
Professional options setups generated by AI based on today's COLL price and gamma walls.
